Concept Strengthens its Assay Development Capabilities With New Hire
Dr Andrew Clifton joins Concept Life Sciences as Head of Bioassay Development and Screening Technologies. Concept Life Sciences offers tailored preclinical services including integrated drug discovery programs. Dr Clifton strengthens the existing industry team at Concept and will be responsible for providing assay development and screening capabilities to support preclinical drug discovery projects from hit finding through to candidate selection.
Andrew has over eighteen years’ experience in both large pharma and biotech through his roles at AstraZeneca and Redx Pharma. Andrew’s expertise is in biochemistry and pharmacology with experience across major drug target classes including a wide variety of enzymes and GPCRs. He has extensive experience of assay development and screening applied to hit finding, hit to lead and lead optimization and has contributed to the delivery of multiple clinical candidates. His therapy area experience includes oncology, inflammation/fibrosis and respiratory. Prior to commencing his pharmaceutical career, Andrew completed his doctoral training with Professor Sir Philip Cohen at the University of Dundee MRC Protein Phosphorylation Unit.
Commenting on his appointment Andrew stated: “I am delighted to be joining Concept Life Sciences at this exciting time in its development. Concept is generally recognized as a leading global provider of preclinical drug discovery services, and I look forward to building our assay development and screening capability to support integrated drug discovery projects. I also look forward to supporting the groups many integrated discovery and development partners, from virtual biotech’s to big pharma.”
Commenting on Dr Clifton’s appointment, Dr Chris Doe, Head of Biology at Concept Life Sciences said: “I am thoroughly delighted to welcome Dr Andrew Clifton to the team. Andrew’s expert knowledge and track record in this field will further strengthen our existing team and underpin our services as a leading UK CRO in Integrated Discovery & Development Services.”
This article has been republished from materials provided by Concept Life Sciences. Note: material may have been edited for length and content. For further information, please contact the cited source.
Study Reveals How MRSA Infection Compromises Lymphatic FunctionNews
Infections of the skin or other soft tissues with the hard-to-treat MRSA bacteria appear to permanently compromise the lymphatic system, which is crucial to immune system function. Investigators describe how MRSA infection impairs the ability of lymphatic vessels to pump lymphatic fluid to lymph nodes in mouse models, which may contribute to the frequent recurrences of MRSA infection experienced by patients.
Possible Biomarker to Identify Who Would Benefit from ImmunotherapyNews
While immunotherapy has made a big impact on cancer treatment, the fact remains that only about a quarter of patients respond to these treatments. In a new study, researchers examined tissue samples from melanoma and ovarian cancer patients treated with immunotherapies and found a link between the percentage of antigen-presenting cells expressing PD-L1 and an objective clinical response to treatment.READ MORE